文献速递肝病消化道肿瘤与早癌

基于无创标志物的模型可预测丙型肝炎病毒晚期纤维化患者病毒学应答后极低肝细胞癌风险

A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus-Advanced Fibrosis.
PubMed 文献 · Hepatology · 2020-11-10

这项多中心队列研究纳入993例直接抗病毒药物获得持续病毒学应答的HCV代偿期晚期纤维化患者,随访中位45个月,35例发生HCC。基于基线LSM、白蛋白、1年LSM变化及1年FIB-4的模型可识别HCC极低风险人群,评分0分者3年HCC发生率为0%。

要点

  • 基线LSM、白蛋白、1年ΔLSM及1年FIB-4为HCC独立相关因素。
  • TE模型评分0分者3年HCC发生率0%,评分1-3分者为5.2%。
  • 基线及动态无创标志物组合有助于识别SVR后HCC极低风险患者。

核心结论

  • 基线及动态无创标志物组合可能有助于识别持续病毒学应答后肝细胞癌极低风险患者。

研究设计与样本

  • 多中心队列研究,纳入直接抗病毒药物治疗后获得持续病毒学应答的HCV代偿期晚期纤维化患者993例(男性56%,女性44%,中位年龄62岁),中位随访45个月(范围13-53个月)。

主要发现

  • 35例发生肝细胞癌(3.9%)。
  • 基线LSM(HR 1.040;95%CI 1.017-1.064)、血清白蛋白(HR 0.400;95%CI 0.174-0.923)、1年ΔLSM(HR 0.993;95%CI 0.987-0.998)及1年FIB-4评分(HR 1.095;95%CI 1.046-1.146)为HCC独立相关因素。
  • TE模型评分0分(基线LSM≤17.3 kPa、白蛋白>4.2 g/dL且1年ΔLSM>25.5%)者3年HCC发生率为0%,评分1-3分者为5.2%(Harrell's C 0.779;log-rank P=0.002)。
  • 基于FIB-4的替代模型同样可预测HCC风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Patients with hepatitis C virus (HCV) and advanced fibrosis remain at risk of hepatocellular carcinoma (HCC) after sustained viral response (SVR) and need lifelong surveillance. Because HCC risk is not homogenous and may decrease with fibrosis regression, we aimed to identify patients with low HCC risk based on the prediction of noninvasive markers and its changes after SVR. APPROACH AND RESULTS: This is a multicenter cohort study, including patients with HCV and compensated advanced fibrosis that achieved SVR after direct antivirals. Clinical and transient elastography (TE) data were registered at baseline, 1 year, and 3 years after the end of treatment (EOT). All patients underwent liver ultrasound scan every 6 months. Patients with clinical evaluation 1 year after EOT were eligible. Univariate and multivariate Cox regression analysis were performed, and predictive models were constructed. HCC occurrence rates were evaluated by Kaplan-Meier. Nine hundred and ninety-three patients were eligible (56% male; 44% female; median age 62 years), 35 developed HCC (3.9%), and the median follow-up was 45 months (range 13-53). Baseline liver stiffness measurement (LSM) (HR 1.040; 95% CI 1.017-1.064), serum albumin (HR 0.400; 95% CI 0.174-0.923), 1-year DeltaLSM (HR 0.993; 95% CI 0.987-0.998), and 1-year FIB-4 score (HR 1.095; 95% CI 1.046-1.146) were independent factors associated with HCC. The TE-based HCC risk model predicted 0% of HCC occurrence at 3 years in patients with score 0 (baseline LSM ≤ 17.3 kPa, albumin >4.2 g/dL, and 1-year DeltaLSM > 25.5%) versus 5.2% in patients with score 1-3 (Harrell's C 0.779; log-rank 0.002). An alternative model with FIB-4 similarly predicted HCC risk. CONCLUSIONS: A combination of baseline and dynamic changes in noninvasive markers may help to identify patients with a very low risk of HCC development after SVR.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Alonso López S, Manzano ML, Gea F, et al. A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus-Advanced Fibrosis. Hepatology. 2020. PMID: 33022803. doi:10.1002/hep.31588

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。